Introduction
Several studiesh aves hown that elevatedl evelso fc oagulation factor VIII (FVIII)are an important risk factor of venous thrombosis. This risk remains after adjusting for the main determinants of FVIII levels, ABO blood group and vonW illebrand factor (VWF) (1) (2) (3) (4) (5) (6) (7) (8) . FVIII activity (FVIII:C) ≥ 150 IU/dl increases the risk of afirst venous thrombosis five-foldc ompared to levels below100 IU/dl. The frequencyofFVIII:C ≥ 150 IU/dl among thrombosis patients is 25%. Since these levels are foundin10% of the population, the contribution of elevatedFVIII levels to all thrombotic eventsinthe population is considerable (1) .
Several linesofevidencesupportthe idea that high FVIII levels are indeed causativetothrombosis and not aconsequence of the thromboticevent, such as adose-dependent relationshipwith risk (1) , persistenceo fe levatedl evelso vert ime (4) , no indications for an acutephase response (9) ,the induction of thrombosis by high FVIII in mouse models (10) ,dependency on ABO blood group and the familialclustering of FVIII levels (11) . The latter, familialclustering,supports the hypothesis that FVIII levels are, at leastinpart, determinedgenetically (12) . So far, no genetic variationshavebeen foundinthe gene encoding FVIII that areassociatedwith an increase in levels and thrombotic risk (6, 13) . Recently however, as ingle nucleotide polymorphism (SNP), c94901g (14) , causing an amino acidc hange in the Bdomain of FVIII,Asp1241Glu (D1241E), hasbeen reportedto be associated with ad ecreasei nF VIII:C.M achiah et al. ( 15) found that this polymorphism accounts for approximately 5% of the total variation in FVIII:Cinthe familiesofthe GAITstudy. Morer ecently,S canavini et al. ( 16) reported that 1241E is as-sociatedw ith an 11%r eduction in FVIII:Ci n1 45 healthy womena nd 150 thromboticw omen. Since high FVIII:C increases the risk of thrombosis,c onditions associated with reducedF VIII:C levels are expected to be associated with ad ecreaseinrisk. However, Machiah et al.did not report estimations on risk,and Scanavini et al. did not find significant differences in genotype distribution between cases and controls (15, 16) .
It is unclear through whichm echanism the 1241E variant could influencel evelso fF VIII. Scanavini et al.h ypothesized thatthe variation might be involved in APC resistance, butcould not demonstrate this (16) .Itisverywellpossible that D1241E is not causal to the decrease in levels, butthat c94901g encoding D1241E is in linkage disequilibrium with the causal variation. On thewebsite of SeattleSNPs (14) , SNPand haplotype data are presentedf or aw ide variety of genes, includingt he gene encoding FVIII.These data arebased on the re-sequencingofthese genesi n2 3s ubjects of European-Americand escent.I nt his population the SNP c94901g encoding 1241E is present in at least threedifferent haplotypes of whichpossibly onlyone could be responsible for the reported effects on FVIII levels.
To investigatethe influenceonFVIII:C and on therisk of venous thrombosis,w es tudiedt he effect of these threec ommon haplotypes encoding the 1241E variant in the LeidenT hrombophiliaS tudy (LETS),al arge population basedc ase-control study on venous thrombosis.Associations found between these haplotypesand FVIII:C in the LETS were alsoevaluatedinthe control subjects of twol arge population-basedc ase-control studiesonarterial thrombosis, the Study of MyocardialInfarctions Leiden (SMILE),c onsisting of men under the age of 70 years,a nd the Risk of Arterial Thrombosis In Relation to Oral ContraceptivesStudy (RAT IO), consisting of womenunder the age of 50 years.
Patientsand methods

Study populations
Leiden Thrombophilia Study(LETS)
The LETS consists of 474 consecutive patients and 474 controls. All patients were referred for anticoagulant treatment after afirst objectivelyconfirmed episode of deepveinthrombosis without an underlying malignancy. Controls were matchedf or sexa nd age and were acquaintances or partners of the patients. Mean age forboth patients and control subjects was45years,ranging from 15 to 69 years forpatients and 15 to 72 years forcontrols. Both groups consisted of 272 women(57.4%) and 202 men (42.6%). All patients and controls were of Dutch origin. DNAs amples were availableo f4 71 cases and 471 controls. FVIII:C was measured in the plasma of allparticipants by aone-stage clotting assay. Levels are expressed as IU/dl (1).VWF:Ag wasmeasured by ELISA in the plasmaofthe first 301patients and 301con-trols. Levels are expressed as IU/ml (1).Pooled normal plasma, calibrateddirectly againstthe WHOstandard for VWF and FVIII (91/666)was used as areference. In each assay, twocontrol plasmas were includedf or inter-assayq uality assurance. Plasma samples had not beenthawedand refrozenbefore these measurements. Thedesign of this studyhas previously beendescribed in moredetail (17) .
StudyofMyocardialInfarctions Leiden (SMILE)
The SMILE consists of 560 patientsand 646 control subjects of whicho nlyt he controls were includedh ere. Casesw ere men belowthe age of 70, diagnosedwith afirst myocardialinfarction. The control group consisted of men whow ere referred to the LeidenAnticoagulation Clinic for prophylactic anticoagulation therapyfor ashortperiod followingminor orthopaedicinterventions.C ontrols did not have ah istoryo fm yocardiali nfarction and had not used anticoagulants for ap eriod of at leasts ix monthsp rior to participating in this study. Controls were frequencymatched to cases on 10-year age groups. All patients and controls were of Dutch origin. Plasmaand DNAsamples were availableo fa ll participants. Plasma FVIII:Cw as measured in twodilutionsbyaone-stage clotting assaywith FVIII deficient plasma and automated activatedp artialt hromboplastin time (APTT,O rganonT eknika,B oxtel, TheN etherlands)o naS TA (Diagnostic Stago, BoehringerM annheim, Mannheim, Germany). Levels are expressed as IU/dl. Pooled normal plasma, calibrated against an in-house standard,w hich wasc alibrated againstt he WHOs tandard for VWF and FVIII (91/666), was used as areference. In each assay, twocontrol plasmas were included forinter-assayquality assurance. Plasma samples had not beenthawedand refrozenbefore these measurements. Exclusion criteriafor this study were renal disease, severe (neuro-)psychiatricproblems or alifeexpectancyoflessthan one year.The design of this study has previouslybeen described in moredetail (18) .
Risk of Arterial ThrombosisinRelation to OralContraceptives Study(RATIO)
The RATIO is acase-controlstudy with patients with different vascularevents (ischemic stroke, peripheral vasculardiseaseand myocardiali nfarction) and healthyc ontrols, of whicho nlyt he controls were includedhere. Thecontrol group consisted of 925 womenbetween the ages of 18 to 49 whohad no historyofcoronary, cerebral,orperipheral arterial disease. Controls were selected viaRandom DigitDialling. Only controls of whichplasma samplesw ere available(639 women) were includedfor the current study.Ninety-three percent of the controls were Caucasian.
PlasmaFVIII:C wasmeasured in twodilutionsinduplicate by ao ne-stage clotting assayw ith FVIII deficient plasma and automated activatedp artialt hromboplastin time( APTT,O rganonT eknika)o naS TA (Diagnostic Stago, BoehringerM annheim). Levels are expressed as IU/dl. VWF:Ag wasmeasured by ELISA, using polyclonal antibodies (Dako,H igh Wycombe, UK).Levelsare expressed as IU/dl. Pooled normal plasma, calibrated against an in-house standard whichwas calibrated against the WHO standard forVWF and FVIII (91/666)w as used as a reference. In each assay,two control plasmaswere includedfor inter-assayq uality assurance. Plasma samples had not been thawedand refrozenbefore these measurements. The design of this study haspreviouslybeen described in moredetail(19).
Combinedcontrol populations
Becausethe FVIII gene is located on the X-chromosome, effects were studiedindetailinmen and womenseparately. Combining the different control populations,two largecontrol groups were formed,a ll male and allf emale, respectively. The first control group consisted of all male control subjects from the LETS and all control subjects from the SMILE.The second control group consisted of all female control subjects from the LETS and all control subjects from the RATIO.B ecausec ontrols were selected stratified forage and because age is known to influence FVIII levels, allanalyses on levels were repeated after adjusting for age using linear regression. VWFl evelsa nd blood group were notdeterminedinall individuals, so overallcorrection for these factorsw as notp ossible. Analysesw ere also performed after normalization of levels perstudy.
Geneticanalysis
AccordingtoSeattleSNPs (April2004), the SNP encoding the 1241E variant is present in at leastthreeFVIII haplotypes,indicated throughout this paperasHT1, HT3 and HT5. Haplotypes aredepicted in Table1.Inorder to identifycarriers of these haplotypes, c94901g [ numbering according to SeattleSNPs,April 2004 (14) ;rs1800291] ,encoding D1241E wasdeterminedinall individuals. Subsequently, twohaplotypetagging SNPs specific for HT3 and HT5,g 24052a (rs6655259) and g27882c (rsnumber pending),respectively, were determinedinboth heteroand homozygous carriers of the 1241E encoding allele.G enotypingwas performed using eitherpolymerase chain reactionrestriction fragment length polymorphisms analyses (PCR-RFLP) or 5'nuclease/Taqman assays.
The polymerase chain reactions with fluorescent allele-specificoligonucleotide probes(Assay-by-Design, AppliedBiosystems, Foster City,CA, USA) and for PCR-RFLPwere performed on aPTC-225 thermal cycler (Biozym, HessischOldendorf, Germany). Fluorescence endpoint reading for allelicd iscrimination of the 5'nuclease/Taqman assaywas done on an ABI7900 HT (Applied Biosystems). PCRconditions, restriction endonucleasesand the sequencesofprobes and primers used for genotypingare availableonrequest. Genotyping wassuccessful in all buteight samplesfor g24052a (threefrom the LETS, fourfrom the SMILEa nd one from the RATIO)a nd twos amples for g27882c (1 from the SMILE and 1from the RATIO).Therewas no evidencefor the existenceofotherhaplotypes thanthe three proposedbySeattleSNPs.
Sequencing
All exons and exon-intron boundaries of the FVIII gene were sequenced in DNAsamples of nine individuals. Selection criteria for these individualsare described under "Results".
PCR Primers for all 26 exons of the FVIII gene were designed from the FVIIII reference sequence (Accession number AH002692.1).The primersare extendedeitherwith an M13-forward or with an M13-reverse sequence. Allp rimers were designed to include completee xon-intron transitions. Fragments for exon 1and exon 14 were split into twoand 10 overlapping fragments, respectively.P CRs were performed in a2 5-µl reaction volume,with afinalMgCl 2 concentration of 1.5 mM except forexon 13. All PCRprogramsincludedaninitial denaturation of 5min by 95°C,followedby35cyclesof30sat94°C,30sat either55°C,53°C,or50°C and afinalextension at 72°C wasperformedfor 5min. ThePCR products were sequenced in both forward and reverse direction on an ABIPrism 3730 DNAAnalyzer (AppliedBiosystems) usingthe ABI Prism BigDyeT erminator Cycle Sequencing Ready Reaction Kit (AppliedB iosystems). The rawsequence datawere analyzed using SeqScape Software forcomparative sequencing analysis (AppliedBiosystems).All primers and PCR-conditions are availableonrequest.
Statisticalanalyses FVIII:Clevelsare presented as means with their standard deviation (SD). To evaluate the difference in levels between groups Student'st-test wasused. The differences,together with the 95% confidencei ntervals (CI95)o ft he differences, areg iven. The differencesi nF VIII levels between groups were alsos tudied after adjustment for age using linear regression. To evaluate the influenceo ft he different geno-and haplotypes on the risk of thrombosis,odds ratios (OR) and their corresponding CI95 according to Wo olf (20) were calculated. ORs were corrected for levels of FVIII using logistic regression.
Results
c94901g,e ncoding D1241E, wasi nH ardy-Weinberg equilibrium for the femalecontrols of the LETS and RATIO.The haplotypes present in the LETS, SMILE and RATIO were in accordance with thosereported by SeattleSNPs. Haplotype frequencies were slightlylower thanpreviouslyreported (14) .Theywere approximately 14% for HT1 and 2% for both HT3 and HT5 in all threestudies.
FVIII haplotypes and levels of FVIII
Effects of the FVIII genevariations on levels of FVIII in controls of the separate studiesare presented in Tables 2A and B. Results  and analyses of the combined control groups arep resentedi n  Tables 3A and B. ForD 1241E in all the controls combined,l ower levels of FVIII:Cwere observed in the absence of the 1241D encoding allele.H eterozygousc arriers and homozygous wildtype carriers had similar levels of FVIII.
In both the separate as well as the combined male control groups, hemizygous carriers of the 1241E encoding alleleshad lowerlevelsofFVIII (Tables 2A and 3A) . In thecombined control group, FVIII:C wasreduced by 6%. Looking at the threesep- aratehaplotypes,HT1, HT3 and HT5, the reduction disappeared for carriers of HT3.For carriers of HT5,areduction in FVIII:C waso bserved; however, withw ide confidencei ntervals. Also, correction for age made the reduction muchsmallerwhile confidenceintervals remained wide. ForHT1 however, the 6% reduction in FVIII:Cremained (Table 3A) . In the femalecontrol groups, no clear effect of the 1241E encoding allelesonlevelsofFVIII wasobserved (Tables 2B and  3B) . Also, the separate haplotypesshowednoconsistent effects.
In both the male and the female control group, VWF:Ag, whichwas measured in the RATIOand in partofthe LETS only, wasnot influenced by eitherD1241E or by the three haplotypes. In thoses ubgroups where VWF and ABOb lood group were measured,correction for VWFand blood group did not influence the outcomes.
FVIII haplotypes and the risk of venous thrombosis
Theriskofvenous thrombosisinthe LETS (Table4A) Overall,men and womencombined,1241E appeared to slightly decrease the risk of venous thrombosis.Homozygous carriers of the Eencoding alleleshad an OR of 0.7(CI95 0.4-1.1).When stratified for haplotypes, it became clear that this risk reduction wascaused by HT1. Homozygous carriers of HT1 had an OR of 0.5 (CI950.3-0.9). ForHT3 and HT5 no reduction in risk was observed.
Theriskofvenous thrombosisinmen (Table4B)
In menalone we found amore pronounced protective effect of the 1241E encoding allelesagainst venous thrombosis.Carriers of 1241Ehad an OR of 0.5(CI95 0.3-0.9).After stratification for haplotypes this reduction in risk remained mainlyfor HT1. It wasevenmore pronounced for carriers of HT1 for whichthe OR was0.4 (CI95 0.2-0.8). Ta ble3:A)FVIII:C(IU/dl) in all male controlsubjectsfromthe LETS and SMILE. Δ is thedifference between themeans given with thecorrespondingCI95. Δ *isthe difference between themeandistancestothe regression lineafter linear regression adjusting forage. HTx signifiesall haplotypes but theone given. B) FVIII:C(IU/dl) in all femalecontrol subjectsfromthe LETS and RATIO. Δ is thedifference between themeans given withthe corresponding CI95 calculated vs. the wildtype (D /Dor HTx /HTx). Δ *isthe difference between themeandistances to theregression lineafter linear regression adjusting forage.HTx signifiesall haplotypes but theone given.
Male
After adjustment for FVIII:Cwith logistic regression, the OR forHT1 in men was0.5 (CI95 0.2-1.0). The reduction in FVIII levels accounted forpartofthe reduction of the risk of venous thrombosis,but HT1 seems to influencerisk in amanner independent of levels as well. HT3and HT5 were too rare to allow meaningfulrisk estimates.
Theriskofvenous thrombosisinwomen(Ta ble 4C)
In women, virtuallynoeffect on the risk of venous thrombosis waso bserved. Forb oth hetero-and homozygous carriers of 1241E, the OR wasapproximately1.SimilarORs were observed for heterozygouscarriers of HT1and HT5 and homozygous carriers of HT1.I nh eterozygousc arriers of HT3, the risk appeared increased (OR 2.3); however, the confidenceintervalwas wide (0.7-7.6).
Sequencingofthe FVIII gene
The effects observedonlevelsofFVIII and therisk of thrombosis appeared to depend mainlyo nH T1. To identifyh aplotypespecificv ariations thatm ay explain this effect, all exons and exon-intron boundaries of the FVIII gene were sequenced in nine male individuals, threeper haplotype. Individualswere selected on phenotype forH T1. Three male controls from the LETS, hemizygous for HT1, were chosen with FVIII:C<100 IU/dl because of the protective effect on venous thrombosis in men and the reduction in FVIII:C associated with HT1. HT3 and HT5 appearedn ot to be associated with anyp articularp henotype. Therefore,f or both HT3 and HT5 threeh emizygous male carriers were selected withoutreference to FVIII levels.
Besidesthe SNPsalready reportedbySeattleSNPs, no haplotype-specific variationsw ere found. Since none of these previouslyreported variationsare likelytoinfluence either protein levels or protein function,itispossible that functional variations lie in intronic regionsofthe FVIII gene.
Discussion
ElevatedlevelsofFVIII are an important riskfactor forvenous thrombosis. There are strongindications that FVIII levels are, at leastinpart, determinedgenetically,beyond the well-known effect of ABOb lood group. To assess whether the D1241Ev ariation in the B-domain of FVIII, whichi np reviouss tudiesw as linked to FVIII levels, is indeed causativetothe previouslyreported effectsonFVIII:C (15, 16), we genotypedtwo additional SNPs to tagthreehaplotypes thatall carry the minor allele of this variation.
We studiedthese threehaplotypes separatelyinthe LETS and in the control populations of the SMILE and the RATIO studies. In general, FVIII:C wasrelativelyhigh in allthreestudies. It was shown previously in the LETS thatt his is not ar esulto fa ctivation (6) since FVIII:Cwere stronglyassociatedwith the actual proteinconcentration (FVIII:Ag).Nor were these high FVIII levels the result of an acutep hase response (9) .The high mean FVIII levels were notthe result of ashift in the distribution of ABO blood groups (LETS control group, 42.6% with blood group O).Sothereisnoexplanation for the overallslightlyelevated FVIII levels in our studypopulations. However, this elevation doesnot affect analysescomparing effects of the different geno-and haplotypes within these populations.
We observeda na ssociation between 1241Ea nd lower FVIII:C, butinmen only.Inmen, areduction of approximately 6% in FVIII:C waso bservedi nt hose individuals with 1241E. After stratifying for haplotypes, this effect appeared to be restricted to HT1. The data also implyareductivetrend of FVIII:C for HT5,w hich is geneticallyv erys imilart oH T1. Howeveri f HT1 and HT5 are looked at as one haplotype, thee ffectsa re weaker thenfor HT1 alone.
In contrasttoScanavini et al. (16) , whodescribed an 11%re-duction in FVIII:Cinfemalecarriers of the 1241E encoding alleles, we found no effects in femalecontrol subjects. Stratifying for haplotypes made no difference.Thereare fewdifferences between the femalecontrols from the LETS and the RATIO and the controls used by Scanavini et al. ( 16) that could explain these contrasting results. Scanavini et al. (16) excluded users of oral contraceptives,whereaswedid not. However, exclusion or inclusion of oral contraceptiveu sers is highlyu nlikelyt oh avei nfluencedthe resultsofD1241E in either study.Sinceprescription of oral contraceptives does notdependongenotype,thereisno reasontoassume thatoral contraceptives users will be unequally distributed over the different geno-and haplotypes.
In summary,w es howedt hat in our study populations ar eduction in FVIII:Cisrestrictedtomalecarriers of HT1, indicating thatt herei sa nother variation on this haplotype thati nfluencesF VIII:C in men only. There is no satisfactorye xplanation for the discrepancyineffectsbetween the twosexes.
As expected,weobserveddecreases in risk of venous thrombosis in the group where FVIII levels were decreased.I nm ale carriers of 1241Eand particularly carriers of HT1, whoshowed a6 %r eduction in FVIII:C, as trong protection againstv enous thrombosis wasobserved. It is tempting to hypothesize that this reduction in risk is caused solelybythe reduction in FVIII levels; however, logistic regression showedthat onlyasmall part of this effect is caused by the reduction in FVIII:C. Nonetheless, similartothe role of ABO blood group, this again is an indication for acausativeassociation between FVIII:Cand the risk of venous thrombosis.Besidesthe small effect HT1 has on the risk of venous thrombosis via areduction in FVIII:C, adjustment with logistic regression showedusthat HT1 influences the risk of venous thrombosis in amanner independent of FVIII levels as well.
Thed atap resentedh ere suggest thatt he effects associated with D1241E arelimitedtoHT1. Thus, D1241E is not likely to be the functional variation responsiblefor the effect on FVIII levels and thrombosis risk as it is present in allthreehaplotypes. Indeed,sofar,nomechanisms for the functionality of D1241E have beeni dentified. The B-domain of the FVIII molecule,i n whichD1241E is located,isnot necessary for procoagulant activity (21)but probablyplays an important roleindetermining levels of FVIII in the circulation (22) . TheB-domain is heavily glycosylated. At least 19 of the 25 N-linked glycosylation sites on FVIII arelocated in the B-domain (23, 24) . It has beenshown that these sites playanimportant roleinthe secretion of FVIII (25) and that theymay also influenceFVIII clearance from the circulation (26) . Then earestN -linked glycosylation site to D1241E, however, is 14 residues away.Although it cannot be excluded,the minor change in the side group from aspartic acidto glutamic acid makes it highlyu nlikelyt hat D1241E would influence glycosylation in the B-domain.
After re-sequencing of the FVIII gene,w ed id not identify other possibly functional variationsspecific for HT1. However, we onlysequenced exons and exon-intron boundaries, so additional variationsu ndoubtedlye xist within non-coding regions. So even though no functional variant wasf ound in HT1, and numbersofcarriers of the othertwo haplotypes, HT3 and HT5, remained very small, we should seriouslyconsider the possibility of the existenceofanasyet unidentifiedfunctional mutation in HT1 other than D1241E. At the same time, the possibilityalso exists thatasy et unidentifiedv ariations in HT3and HT5 exist thatcounteractthe effects of D1241E, masking its functionality in these twohaplotypes.
In conclusion,w eobservedareduction in FVIII:Cthat was restricted to male carriers of HT1. HT1was also associatedwith adecreaseinrisk of venous thrombosis.Asmall part of this decrease in risk could be explained by the reduction in FVIII levels. In addition, HT1had aprotective effect againstvenous thrombosis, whichcould not be explained by the reduction in FVIII:Cas well. Althoughthis should be investigated further,itispossible that D1241E is not the main playerinthese effects, since both carriers of HT3 and HT5 apparently shownoreduction in either FVIII:Corinthe risk of venous thrombosis.
